Deferiprone: greater efficacy at depleting myocardial than hepatic iron?
Richardson
Des R
DR
Children's Cancer Research Institute Australia, Iron Metabolism and Chelation Program, Randwick, Sydney, NSW 2031, Australia. d.richardson@ccia.org.au
D000077543:Deferiprone; D003676:Deferoxamine / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007501:Iron / Q000378:metabolism*; D007502:Iron Chelating Agents / Q000627:therapeutic use*; D008099:Liver / Q000378:metabolism*; D009206:Myocardium / Q000378:metabolism*; D011728:Pyridones / Q000494:pharmacology / Q000627:therapeutic use*; D017086:beta-Thalassemia / Q000188:drug therapy
D007502:Iron Chelating Agents; D011728:Pyridones; D000077543:Deferiprone; D007501:Iron; D003676:Deferoxamine